Last 24 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -10.74 | 0.53 | — | — | 0.35 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 105.64 | — | 60.17 | 32.66 | 26.50 | 17.85 | 34.58 | 282.07 | 43.62 | 49.44 | — | 106.50 | — | — | — | — | — | — | — | — | — |
| — | — | +74.0% | -88.4% | -39.3% | -63.9% | — | +164.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.66 | 0.98 | 1.01 | 0.50 | 0.36 | 0.33 | 0.54 | 0.70 | 0.74 | 0.74 | 0.85 | 0.91 | 1.11 | 1.64 | 1.48 | 1.38 | 3.38 | 1.56 | 1.30 | 1.62 | 2.60 |
| — | +198.2% | +87.1% | -28.0% | -51.6% | -55.4% | -35.9% | -24.0% | -33.3% | -55.0% | -42.9% | -33.6% | -67.3% | +5.0% | +14.1% | -14.8% | +30.1% | — | — | — | — | |
| P/FCF | — | 0.51 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | -0.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.3% | — | 98.6% | -1546.4% | -1854.2% | -2765.1% | -2600.5% | 21.1% | 100.0% | 88.6% | — | 50.0% | — | — | — | — | — | — | — | — | — |
| — | — | +103.8% | -7445.4% | -1954.2% | -3219.9% | — | -57.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -3270.9% | — | -2232.5% | -2888.3% | -3266.5% | -4743.9% | -4561.3% | -30547.4% | -4035.5% | -5697.3% | — | -9259.6% | — | — | — | — | — | — | — | — | — |
| — | — | +51.1% | +90.5% | +19.1% | +16.7% | — | -229.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -1046.4% | — | -3904.7% | -2636.0% | 7554.7% | -4576.9% | -4452.4% | -29063.2% | -3834.8% | -5430.1% | — | -8878.1% | — | — | — | — | — | — | — | — | — |
| — | — | +12.3% | +90.9% | +297.0% | +15.7% | — | -227.4% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -15.0% | 60.3% | -15.3% | -9.7% | 29.4% | -19.4% | -16.3% | -16.7% | -15.2% | -19.2% | -19.5% | -17.6% | -14.0% | -12.7% | -10.7% | -10.8% | -13.1% | -11.3% | -8.6% | -6.9% | -6.8% |
| — | +411.0% | +6.2% | +42.0% | +293.3% | -1.1% | +16.3% | +5.4% | -8.7% | -51.7% | -82.5% | -63.8% | -6.5% | -11.9% | -24.7% | -56.9% | -92.6% | -19.9% | +16.4% | +50.2% | +70.4% | |
| ROA | -13.8% | 57.3% | -14.2% | -9.0% | 27.0% | -17.8% | -15.0% | -15.0% | -13.4% | -16.9% | -17.7% | -16.3% | -13.1% | -12.0% | -10.1% | -10.0% | -12.3% | -10.8% | -8.2% | -6.6% | -6.5% |
| — | +421.5% | +5.3% | +40.0% | +301.8% | -5.2% | +15.4% | +7.7% | -2.2% | -40.8% | -75.2% | -62.7% | -6.6% | -11.1% | -22.5% | -51.4% | -89.0% | -21.3% | +15.7% | +10.9% | — | |
| ROIC | -56.4% | -78.7% | -19.8% | -16.6% | -15.3% | -19.9% | -16.6% | -18.6% | -16.6% | -19.1% | -19.5% | -16.9% | -13.7% | -13.5% | -12.0% | -13.2% | -16.8% | -15.5% | -26.0% | — | — |
| — | -296.3% | -19.1% | +10.6% | +7.3% | -4.0% | +14.8% | -9.8% | -20.8% | -41.6% | -62.0% | -28.0% | +18.4% | +13.2% | +53.8% | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| — | — | +42.8% | +21.6% | -3.3% | -64.4% | -43.6% | -32.3% | -6.2% | +3.2% | +13.9% | +12.6% | -22.9% | -19.0% | -18.2% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 14.50 | 27.26 | 12.92 | 14.50 | 14.74 | 9.98 | 14.68 | 10.87 | 9.55 | 7.52 | 9.77 | 12.39 | 14.08 | 18.23 | 23.72 | 16.71 | 12.61 | 21.20 | 28.93 | 27.61 | 26.20 |
| — | +173.3% | -12.0% | +33.5% | +54.3% | +32.7% | +50.2% | -12.3% | -32.2% | -58.8% | -58.8% | -25.8% | +11.7% | -14.0% | -18.0% | -39.5% | -51.9% | +32.6% | +36.6% | +14.2% | — | |
| Quick Ratio | 14.50 | 27.26 | 12.92 | 14.50 | 14.74 | 9.98 | 14.68 | 10.87 | 9.55 | 7.52 | 9.77 | 12.39 | 14.08 | 18.23 | 23.72 | 16.71 | 12.61 | 21.20 | 28.93 | 27.61 | 26.20 |
| — | +173.3% | -12.0% | +33.5% | +54.3% | +32.7% | +50.2% | -12.3% | -32.2% | -58.8% | -58.8% | -25.8% | +11.7% | -14.0% | -18.0% | -39.5% | -51.9% | +32.6% | +36.6% | +14.2% | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -35.92 | — | -147.61 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RLYB stock.
Rallybio Corporation's current P/E is -10.7x. The average P/E over the last 2 quarters is 0.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Rallybio Corporation's current operating margin is -3270.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Rallybio Corporation's business trajectory between earnings reports.